Ulcerative colitis with multidrug-resistant pseudomonas aeruginosa infection successfully treated with bifidobacterium

Digestion

Volumn 81, Issue 3, 2010, Pages 204-205

  Nagasaki, Azusa ^a   Takahashi, Hirokazu ^a   Iinuma, Mizue ^a   Uchiyama, Takashi ^a   Watanabe, Seitaro ^a   Koide, Tomoko ^a   Tokoro, Chikako ^a   Inamori, Masahiko ^a   Abe, Yasunobu ^a   Nakajima, Atsushi ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

Bifidobacterium; Probiotics; Ulcerative colitis

Indexed keywords

CYCLOSPORIN A; GANCICLOVIR; MESALAZINE; PREDNISOLONE; PROBIOTIC AGENT; SALAZOSULFAPYRIDINE; VANCOMYCIN;

AGED; ANTIBIOTIC THERAPY; ARTICLE; BIFIDOBACTERIUM; CASE REPORT; COLONOSCOPY; CONTINUOUS INFUSION; HUMAN; MALE; PRIORITY JOURNAL; PSEUDOMONAS INFECTION; REMISSION; STAPHYLOCOCCUS EPIDERMIDIS; ULCERATIVE COLITIS;

AGED; BIFIDOBACTERIUM; COLITIS, ULCERATIVE; DRUG RESISTANCE, MULTIPLE; HUMANS; MALE; PROBIOTICS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 74249122432     PISSN: 00122823     EISSN: None     Source Type: Journal    
DOI: 10.1159/000236042     Document Type: Article

References (10)

1. Sartor RB: Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology 2004; 126: 1620-1633.
2. Fiocchi C: Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 1998; 115: 182-205.
3. Isolauri E, Kirjavainen PV, Salminen S: Probiotics: a role in the treatment of intestinal infection and inflammation? Gut 2002; 50: 54-59.
4. Bibiloni R, Fedorak RN, Tannock GW, et al: VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol 2005; 100: 1539-1546.
5. Fujimori S, Gudis K, Mitsui K, et al: A randomized controlled trial on the efficacy of synbiotic versus probiotic or prebiotic treatment to improve the quality of life in patients with ulcerative colitis. Nutrition 2009; 25: 520-525.
6. Takaishi H, Matsuki T, Nakazawa A, et al: Imbalance in intestinal microflora constitution could be involved in the pathogenesis of inflammatory bowel disease. Int J Med Microbiol 2008; 298: 463-472.
7. Damaskos D, Kolios G: Probiotics and prebiotics in inflammatory bowel disease: microflora 'on the scope'. Br J Clin Pharmacol 2008; 65: 453-467.
8. Peran L, Camuesco D, Comalada M, et al: A comparative study of the preventative effects exerted by three probiotics, Bifidobacterium lactis , Lactobacillus casei and Lactobacillus acidophilus , in the TNBS model of rat colitis. J Appl Microbiol 2007; 103: 836-844. (Pubitemid 47493215)
9. Imaoka A, Shima T, Kato K, et al: Anti-inflammatory activity of probiotic Bifidobacterium : enhancement of IL-10 production in peripheral blood mononuclear cells from ulcerative colitis patients and inhibition of IL-8 secretion in HT-29 cells. World J Gastroenterol 2008; 14: 2511-2516.
10. Bai AP, Ouyang Q, Xiao XR, et al: Probiotics modulate inflammatory cytokine secretion from inflamed mucosa in active ulcerative colitis. Int J Clin Pract 2006; 60: 284-288.